Innovative Cellular Therapeutics
Business Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1405 Research Blvd Ste 210, Rockville, M...Phone Number
(240) 690-9110Website
www.ictbio.comRevenue
$6.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a clinical-stage biotechnology company focused on developing next-generation CAR-T therapies to transform cancer treatment globally. Their proprietary platforms, CoupledCAR and INSTACAR, support the research and development of cellular immunotherapies for solid tumors, with a leading product, GCC19CART, targeting relapsed/refractory metastatic colorectal cancer. ICT is expanding its CAR-T candidate portfolio to address various solid tumors and employs the ARMORED CAR platform to enhance therapy effectiveness. The company aims to provide innovative solutions for patients suffering from cancer through advanced immunotherapy strategies.Explore more
Innovative Cellular Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Innovative Cellular Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Innovative Cellular Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Innovative Cellular Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Innovative Cellular Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Innovative Cellular Therapeutics
Funding: Get notified immidiatlly once Innovative Cellular Therapeutics has new funding data
Click to see if Innovative Cellular Therapeutics had a recent Job posting/layoffs
Check out if Innovative Cellular Therapeutics is spiking on competitors!
Earning: See what the market has to say on Innovative Cellular Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at Innovative Cellular Therapeutics
Find 3 more new buyers
Compare Similar Companies to Innovative Cellular Therapeutics
Compare insights from companies similar to Innovative Cellular Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Innovative Cellular Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Innovative Cellular Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Innovative Cellular Therapeutics.
Innovative Cellular Therapeutics financials insights
Gather financial insights about Innovative Cellular Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$28.6M
Innovative Cellular Therapeutics Tech Stack
A closer look at the technologies used by Innovative Cellular Therapeutics
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Innovative Cellular Therapeutics is planning to move offices in November 2023. The move will impact approximately 12 employees at the existing office located at 1405 Research Boulevard,, Suite#210, Rockville, MD.
Facilities Relocation/Expansion
Executive Move
Board of Directors
Left Company
Executive Move
New Hire
Executive Move
Robert Dallimore has joined the organization as Senior Vice President, Quality & Compliance.
Executive Moves, New Hire
New Hire
Executive Move
Innovative Cellular Therapeutics News & Media
Innovative Cellular Therapeutics (ICT) Presented Data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
ROCKVILLE, Md., May 24, 2023 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual meeting in Los Angeles, California. May 16-20, 2023.Innovative Cellular Therapeutics (ICT) Presented Updated Data at the American Association for Cancer Research (AACR) Annual Meeting
ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company presented at the Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida April 14-19, 2023.Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer
ROCKVILLE, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced that the first patient has been enrolled in its Phase I trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC). The study (NCT05319314) is an open-label, single arm, multicenter Phase 1 dose-escalation clinical triInnovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
ROCKVILLE, Md., May 26, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the acceptance of an abstract for poster presentation at the upcoming 2022 ASCO Annual meeting in Chicago, IL from June 3-7, 2022.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Innovative Cellular Therapeutics
Sign Up For FreeTo access detailed company insights
Innovative Cellular Therapeutics (ICT) is a clinical-stage biotechnology company focused on developing next-generation CAR-T therapies to transform cancer treatment globally. Their proprietary platforms, CoupledCAR and INSTACAR, support the research and development of cellular immunotherapies for solid tumors, with a leading product, GCC19CART, tar... Read More
